New Study Identifies Cell Therapy Companies to Watch

05-Mar-2004

New Yorck. A new report released from Kalorama Information identifies 22 cell therapy competitors as "companies to watch." Developed in conjunction with a market research study into cell therapeutics, the list of companies stems from the strength of their technologies, how those technologies fit into market realities, and how well the company is managing its development and financing. The market potential of stem cell and other cellular therapeutics is huge. The technologies have curative potential for conditions such as diabetes, Alzheimer's, spinal injury, and many more. According to the study, there are several areas of cell therapy that will experience triple-digit annual growth in the coming years. "With the exception of a few areas, the industry and the technologies are extremely young; the first large wave of products is unlikely to appear before 2010 or later," notes Share Rosen, the author of the report. "Therefore, competitors must have more than just a good technology. They must have a strong commitment to strategic product development and, frankly, the financial resources to survive." In addition to identifying the companies best situated to exploit the emerging opportunities, the report discusses recent research highlights, important clinical trends, and the unique business environment in which cell therapy companies will be competing. Regulatory, ethical, cost, and reimbursement issues and how they will affect product and market development are considered. "Many of these new devices and technologies are expected to carry a high price tag and the payment infrastructure in most countries has not evolved to cover many of the newer approaches to patient management," warns Rosen. "The onus is, therefore, on manufacturers to prove that their new intervention is not only effective but also cost effective."

https://www.bionity.com/en/news/35898/new-study-identifies-cell-therapy-companies-to-watch.html